The structure of raloxifene
Find information on thousands of medical conditions and prescription drugs.

Evista

Raloxifene is an oral selective estrogen receptor modulator which is used in the prevention of osteoporosis in postmenopausal women. There has been some evidence that raloxifene can reduce the incidence of breast cancer, but this has yet to be proven in a clinical setting. Raloxifene is produced by Eli Lilly Pharmaceuticals and is sold under the brand name Evista.

SERMs mimic estrogen in some tissues and have anti-estrogen activity in others. Other SERMs, such as Pfizer's lasofoxifene and Wyeth's bazedoxifene are in the late stages of clinical development.

Home
Diseases
Medicines
A
B
C
D
E
E-Base
Ecstasy (drug)
Edecrin
Edrophonium
Edrophonium chloride
Efavirenz
Effexor
Eflornithine
Elavil
Eldepryl
Elidel
Eligard
Elitek
Elixomin
Elixophyllin
Ellagic acid
Elmiron
Eloxatin
Elspar
Emtriva
Emylcamate
Enalapril
Enalaprilat
Enalaprilat
Endep
Enflurane
Enoxaparin sodium
Entacapone
Enulose
Epi-pen
Epinephrine
Epirubicin
Epitol
Epivir
Epogen
Eprosartan
Ergocalciferol
Ergoloid Mesylates
Ergotamine
Eryc
Eryped
Erythromycin
Esgic
Eskalith
Esmolol
Estazolam
Estazolam
Estrace
Estraderm
Estradiol
Estradiol
Estradiol valerate
Estring
Estrogel
Estrone
Estrostep
Ethacridine
Ethambutol
Ethchlorvynol
Ethosuximide
Ethotoin
Etiracetam
Etodolac
Etopophos
Etoposide
Etorphine
Evista
Exelon
Exemestane
Hexal Australia
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Evista gets cardiac OK in JAMA - Pharmacy News Briefs - Raloxifene study links drug to decreased risk of heart attack - Brief Article
From Drug Store News, 3/4/02 by James Frederick

CHICAGO -- An article in a recent issue of the Journal of the American Medical Association gave Eli Lilly's osteoporosis drug Evista (raloxifene) a big boost as a potential heart attack preventative. Researchers in a four-year "Multiple Outcomes of Raloxifene Evaluation" study, funded by Eli Lilly, studied the effect of raloxifene in multicenter trials involving almost 8,000 osteoporotic post-menopausal women between November 1994 and September 1999. They found that women entering the study with an already increased risk of cardiovascular problems ended up lowering their risk of cardiac events when taking raloxifene by study's end.

More investigation, however, is needed. "Before raloxifene is used for prevention of cardiovascular events," the researchers said, "these findings require confirmation in trials with evaluation of cardiovascular outcomes as the primary objective."

COPYRIGHT 2002 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2002 Gale Group

Return to Evista
Home Contact Resources Exchange Links ebay